Cathay Biotech Hits Day High with Strong 3.91% Intraday Surge

Cathay Biotech, Inc., a prominent player in the specialty chemicals industry, has experienced a notable uptick in its stock performance today, gaining 3.91% as of March 12, 2026. The stock reached an intraday high of CNY 56.70, reflecting a positive shift in market sentiment despite broader market trends. Over the past week, Cathay Biotech has shown a robust performance with a 7.31% increase, significantly outperforming the China Shanghai Composite, which rose by only 0.5%. Year-to-date, the company has achieved an 11.41% gain, further highlighting its resilience in a fluctuating market environment. Despite these short-term gains, Cathay Biotech's long-term growth metrics indicate challenges, with a five-year annual growth rate in net sales at 13.42% and an operating profit decline of 4.13%. The company has maintained a positive trajectory in recent quarters, reporting consistent results and a notable reduction in raw material costs by 15.64% year-over-year. With a market capitalization of CNY 30,966 million and a price-to-earnings ratio of 71.00, Cathay Biotech continues to navigate a complex financial landscape while delivering solid performance in the specialty chemicals sector.